Cargando…

维奈托克联合利妥昔单抗治疗伊布替尼耐药慢性淋巴细胞白血病一例报告并文献复习

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342882/
https://www.ncbi.nlm.nih.gov/pubmed/31495144
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.08.018
_version_ 1783555619146432512
collection PubMed
description
format Online
Article
Text
id pubmed-7342882
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73428822020-07-16 维奈托克联合利妥昔单抗治疗伊布替尼耐药慢性淋巴细胞白血病一例报告并文献复习 Zhonghua Xue Ye Xue Za Zhi 经验交流 Editorial office of Chinese Journal of Hematology 2019-08 /pmc/articles/PMC7342882/ /pubmed/31495144 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.08.018 Text en 2019年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 经验交流
维奈托克联合利妥昔单抗治疗伊布替尼耐药慢性淋巴细胞白血病一例报告并文献复习
title 维奈托克联合利妥昔单抗治疗伊布替尼耐药慢性淋巴细胞白血病一例报告并文献复习
title_full 维奈托克联合利妥昔单抗治疗伊布替尼耐药慢性淋巴细胞白血病一例报告并文献复习
title_fullStr 维奈托克联合利妥昔单抗治疗伊布替尼耐药慢性淋巴细胞白血病一例报告并文献复习
title_full_unstemmed 维奈托克联合利妥昔单抗治疗伊布替尼耐药慢性淋巴细胞白血病一例报告并文献复习
title_short 维奈托克联合利妥昔单抗治疗伊布替尼耐药慢性淋巴细胞白血病一例报告并文献复习
title_sort 维奈托克联合利妥昔单抗治疗伊布替尼耐药慢性淋巴细胞白血病一例报告并文献复习
topic 经验交流
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342882/
https://www.ncbi.nlm.nih.gov/pubmed/31495144
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.08.018
work_keys_str_mv AT wéinàituōkèliánhélìtuǒxīdānkàngzhìliáoyībùtìnínàiyàomànxìnglínbāxìbāobáixuèbìngyīlìbàogàobìngwénxiànfùxí
AT wéinàituōkèliánhélìtuǒxīdānkàngzhìliáoyībùtìnínàiyàomànxìnglínbāxìbāobáixuèbìngyīlìbàogàobìngwénxiànfùxí
AT wéinàituōkèliánhélìtuǒxīdānkàngzhìliáoyībùtìnínàiyàomànxìnglínbāxìbāobáixuèbìngyīlìbàogàobìngwénxiànfùxí
AT wéinàituōkèliánhélìtuǒxīdānkàngzhìliáoyībùtìnínàiyàomànxìnglínbāxìbāobáixuèbìngyīlìbàogàobìngwénxiànfùxí
AT wéinàituōkèliánhélìtuǒxīdānkàngzhìliáoyībùtìnínàiyàomànxìnglínbāxìbāobáixuèbìngyīlìbàogàobìngwénxiànfùxí
AT wéinàituōkèliánhélìtuǒxīdānkàngzhìliáoyībùtìnínàiyàomànxìnglínbāxìbāobáixuèbìngyīlìbàogàobìngwénxiànfùxí
AT wéinàituōkèliánhélìtuǒxīdānkàngzhìliáoyībùtìnínàiyàomànxìnglínbāxìbāobáixuèbìngyīlìbàogàobìngwénxiànfùxí